Logo image of QLI

QILIAN INTERNATIONAL HOLDING (QLI) Stock Fundamental Analysis

NASDAQ:QLI - KYG7307E1237 - Common Stock

5.41 USD
-0.35 (-6.08%)
Last: 8/9/2024, 8:09:24 PM
Fundamental Rating

3

Overall QLI gets a fundamental rating of 3 out of 10. We evaluated QLI against 195 industry peers in the Pharmaceuticals industry. The financial health of QLI is average, but there are quite some concerns on its profitability. QLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

QLI had negative earnings in the past year.
In the past year QLI had a positive cash flow from operations.
QLI had positive earnings in 4 of the past 5 years.
QLI had a positive operating cash flow in 4 of the past 5 years.
QLI Yearly Net Income VS EBIT VS OCF VS FCFQLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

1.2 Ratios

QLI's Return On Assets of -15.18% is fine compared to the rest of the industry. QLI outperforms 66.84% of its industry peers.
Looking at the Return On Equity, with a value of -18.18%, QLI is in the better half of the industry, outperforming 74.09% of the companies in the same industry.
Industry RankSector Rank
ROA -15.18%
ROE -18.18%
ROIC N/A
ROA(3y)-3.11%
ROA(5y)3.26%
ROE(3y)-3.47%
ROE(5y)7.16%
ROIC(3y)N/A
ROIC(5y)N/A
QLI Yearly ROA, ROE, ROICQLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

1.3 Margins

QLI's Gross Margin of 3.77% is in line compared to the rest of the industry. QLI outperforms 48.70% of its industry peers.
QLI's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for QLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37%
GM growth 5Y-25.24%
QLI Yearly Profit, Operating, Gross MarginsQLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

More info and screens

6

2. Health

2.1 Basic Checks

QLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for QLI has been reduced compared to 1 year ago.
Compared to 5 years ago, QLI has less shares outstanding
Compared to 1 year ago, QLI has an improved debt to assets ratio.
QLI Yearly Shares OutstandingQLI Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
QLI Yearly Total Debt VS Total AssetsQLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

An Altman-Z score of 4.38 indicates that QLI is not in any danger for bankruptcy at the moment.
QLI has a better Altman-Z score (4.38) than 78.76% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that QLI is not too dependend on debt financing.
The Debt to Equity ratio of QLI (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 4.38
ROIC/WACCN/A
WACC8.08%
QLI Yearly LT Debt VS Equity VS FCFQLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M 20M 30M 40M 50M

2.3 Liquidity

A Current Ratio of 5.18 indicates that QLI has no problem at all paying its short term obligations.
With a decent Current ratio value of 5.18, QLI is doing good in the industry, outperforming 61.66% of the companies in the same industry.
QLI has a Quick Ratio of 4.43. This indicates that QLI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of QLI (4.43) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.18
Quick Ratio 4.43
QLI Yearly Current Assets VS Current LiabilitesQLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for QLI have decreased strongly by -3727.33% in the last year.
The Revenue for QLI has decreased by -28.35% in the past year. This is quite bad
The Revenue has been decreasing by -1.60% on average over the past years.
EPS 1Y (TTM)-3727.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3958.33%
Revenue 1Y (TTM)-28.35%
Revenue growth 3Y-2.43%
Revenue growth 5Y-1.6%
Sales Q2Q%-47.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QLI Yearly Revenue VS EstimatesQLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

QLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QLI Price Earnings VS Forward Price EarningsQLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QLI Per share dataQLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QILIAN INTERNATIONAL HOLDING

NASDAQ:QLI (8/9/2024, 8:09:24 PM)

5.41

-0.35 (-6.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-09 2024-02-09
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap38.68M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-22.97%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.83
P/FCF N/A
P/OCF 123.9
P/B 0.9
P/tB 0.98
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)0.04
OCFY0.81%
SpS6.5
BVpS5.98
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.18%
ROE -18.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.77%
FCFM N/A
ROA(3y)-3.11%
ROA(5y)3.26%
ROE(3y)-3.47%
ROE(5y)7.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37%
GM growth 5Y-25.24%
F-Score4
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 178.92%
Cap/Sales 4.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.18
Quick Ratio 4.43
Altman-Z 4.38
F-Score4
WACC8.08%
ROIC/WACCN/A
Cap/Depr(3y)245.66%
Cap/Depr(5y)166.1%
Cap/Sales(3y)5.18%
Cap/Sales(5y)3.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3727.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3958.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-28.35%
Revenue growth 3Y-2.43%
Revenue growth 5Y-1.6%
Sales Q2Q%-47.18%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-224.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-118.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-97.53%
OCF growth 3Y-60.54%
OCF growth 5Y-41.2%